Haemostatic and inflammatory alterations in @entity4310 , and the impact of XXXX infusion.

@entity32 @entity650 @entity2002 @entity753 @entity556 @entity7774 @entity2178 @entity4310 @entity1851
INTRODUCTION: We examined potential prothrombotic and proinflammatory effects of @entity2178 in 16 otherwise healthy @entity4310 subjects and 16 matched controls. METHODS: Markers of fibrinolysis, @entity556 generation and @entity32 were assessed in plasma before, during and 1h after a 3h intravenous infusion of @entity2178 . In addition, placebo experiments with saline infusion were carried out. RESULTS: Baseline plasminogen activator inhibitor type-1 activity and plasmin-antiplasmin-complex concentrations were similar in @entity753 and controls, as were @entity650 , leukocyte counts and @entity1851 . @entity2002 levels were higher in @entity753 , and we observed a greater @entity556 generating potential in @entity753 (calibrated automated thrombogram), but no signs of elevated @entity556 generation in vivo (prothrombin fragment 1+2). During angiotensin infusion plasminogen activator inhibitor type-1 activity decreased and plasmin-antiplasmin-complex concentrations increased similarly in @entity753 and controls. Total and maximal amount of @entity556 generated was unchanged, as were prothrombin-fragment-1+2 levels. @entity650 and leukocyte counts increased similarly in both groups during @entity7774 infusion, while @entity2002 tended to increase in @entity753 and increased in controls. During saline infusion plasminogen activator inhibitor type-1 activity and prothrombin fragment 1+2 concentrations fell, whereas other markers were unchanged. CONCLUSIONS: @entity753 exhibits an increased @entity556 generation potential, an intact fibrinolysis, and has no convincing signs of @entity32 . Angiotensin has proinflammatory effects, and might have minor profibrinolytic and procoagulatory effects.
